Headache
-
Randomized Controlled Trial Clinical Trial
Use of percutaneous electrical nerve stimulation (PENS) in the short-term management of headache.
To evaluate the short-term effects of percutaneous electrical nerve stimulation (PENS) in the management of three types of chronic headache. ⋯ Percutaneous electrical nerve stimulation appears to be a useful complementary therapy to analgesic and antimigraine drugs for the short-term management of headache. Interestingly, the analgesic response to PENS therapy appears to be independent of the origin of the headache symptoms.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study.
To see whether therapy with botulinum toxin A may prove to be an effective treatment for headache of musculoskeletal origin. ⋯ Fourteen subjects who received botulinum toxin A and 12 who received saline completed the study. At both 2 and 4 weeks post injection, the treatment group showed a significant improvement in pain and range of motion from preinjection levels (P<.01). The placebo group demonstrated no statistically significant changes at any posttreatment time.
-
Randomized Controlled Trial Clinical Trial
Intranasal lidocaine for migraine: a randomized trial and open-label follow-up.
To study the efficacy of intranasal lidocaine for the treatment of migraine when administered by subjects in a nonclinic setting. ⋯ Intranasal lidocaine 4% provides rapid relief of migraine symptoms. For those subjects who do respond, the effect does not diminish over 6-month follow-up.
-
Randomized Controlled Trial Clinical Trial
Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group.
To evaluate the efficacy and tolerability of naratriptan, a novel 5-HT1 agonist, in the acute treatment of migraine. ⋯ Naratriptan is effective and well tolerated for the acute treatment of migraine. The 2.5-mg dose appears to offer the optimum ratio of efficacy to tolerability.
-
Randomized Controlled Trial Clinical Trial
Ketoprofen versus paracetamol in the treatment of acute migraine.
The efficacy and safety of ketoprofen and paracetamol were compared for the treatment of acute migraine in a randomized, double-blind study of 64 patients. Thirty-four patients received ketoprofen 100 mg intramuscularly, and 30 patients received paracetamol 500 mg intramuscularly. Partial or complete relief of pain and other symptoms was achieved 15 to 20 minutes after administration in the ketoprofen group and within 35 minutes in the paracetamol group. ⋯ Six of the patients treated with ketoprofen needed a second dose for complete relief of pain during the 4-hour follow-up period. Side effects were rare and minimal. Our findings suggest that ketoprofen produced statistically significant benefit in the treatment of acute migraine.